Retina is producing Phase 3 results faster than ever, but FDA approval doesn't necessarily convey how a drug will fit into practice. Dr. Ehsan Rahimy joins host Dr. Jay Sridhar to unpack recent and somewhat puzzling trial results involving tyrosine kinase inhibitors, IL-6 inhibition, and the Wnt signaling pathway. They then confront the harder problem: When every trial uses a different population, comparator, and dosing scheme—and none tests against today's second-generation anti-VEGF agents—real-world practice is often shaped by anecdote rather than evidence.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Artificial intelligence is rapidly recasting how we interact with our world and our patients. In today's epside, host Dr. Amanda Redfern welcomes Dr. Chris Kelly, Chief Health Information Officer at Oregon Health and Science University (OHSU), to provide an inside look at tools available in the clinic today, what's on the horizon, and why he's bullish about the future of health care in the AI era.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

What's a mom-to-be to do if she's also an ophthalmologist? In part 2 of this two-part series, host Dr. Ben Young invites Dr. Fei Cai, a maternal-fetal medicine specialist and obstetrician, to review the essentials of pre- and postnatal care, what to be mindful of if practicing while pregnant, and how your residency or fellowship training program can be expected to support you.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.